Stock Ratings / Health Care / FRNM / financials

TRUP (64) CSTL (60) ALHC (67) LMRI (58) ⌘ Pro Terminal →

Freenome Inc. (FRNM) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$12.86 -4.32% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.74

Freenome Inc. (FRNM) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $1.38B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $12.74 (-0.97%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-12.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FRNM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY FRNM SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (26% of score)

FRED Regime × Technicals: 39% of 52W Range • RSI-14 at 39.9 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$15.78-25.5% Next Q

Q2 (-2Q)

Grade E$11.75+8.7% Next Q

Q3 (-1Q)

Grade E$12.77+0.7% Next Q

Current

Grade E$12.86-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a FRNM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While FRNM currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.73) and Max Pain ($13.50) forces dealer call-delta covering toward $18.38.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FRNM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “FRNM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How FRNM Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-0.1%	$837.5K	-$864.7K	-45%
FY 2024	$4.00B	52%	0%	$0	$0	-3.4%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FRNM)

✓Walkthrough of FRNM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

FRNM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +13.81%📐 HORIZONTAL RANGE

2026-10-30O $12.64H $12.86L $11.59C $12.86VOL 650.8K

RES: $19.84SUP: $8.01SMA50: $14.73SMA200: $12.51

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FRNM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FRNM Butterfly Map → + Track FRNM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on FRNM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FRNM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for FRNM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FRNM)

Health Care Rank #909 of 1016 ⚔️ TRUP vs FRNM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FRNM vs. TRUP, CSTL, ALHC, LMRI)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Freenome Inc. (FRNM) ranks #909 by composite RQD confidence (31/100, grade E) and #313 by equity capitalization ($1.38B). Within this direct 5-issuer industry benchmark cohort, TRUP leads on earnings valuation at 68.2x trailing P/E, while ALHC leads on capital efficiency and profitability with 13.9% ROIC and — gross margin. ALHC currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with FRNM at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
FRNM ACTIVE Freenome Inc.	E	31/100	—	—	-3.4%	-4.32%	$1.38B	Benchmark Subject
TRUP Trupanion Inc.	C	64/100	68.2x	16.1%	3.1%	+2.27%	$1.32B	/trup-vs-frnm →
CSTL Castle Biosciences Inc.	C-	60/100	—	79.4%	-9.3%	+4.99%	$1.18B	/cstl-vs-frnm →
ALHC Alignment Healthcare Inc.	C+	67/100	—	—	13.9%	-1.47%	$1.67B	/alhc-vs-frnm →
LMRI Lumexa Imaging Holdings Inc.	D+	58/100	—	—	—	+0.95%	$1.13B	/lmri-vs-frnm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002017526

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Freenome Inc. (FRNM) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $837.5K, operating cash flow of -$864.7K, and free cash flow of -$864.7K . On the balance sheet, FRNM closed FY2025 with $92.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$837.5K	-$864.7K	-$864.7K	$92.8M	—
FY2024 (FY)	2024-12-31	$0	$0	—	—	$89.9M	—

3. FRNM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FRNM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Freenome Inc. (NASDAQ: FRNM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $12.86 (-4.32% 1D, market cap $1.38B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, FRNM ranks #909 in composite RQD confidence.

How does FRNM compare to TRUP and CSTL in the Health Care sector?

Within the Health Care sector (Medical Specialities), FRNM carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -3.4%. By comparison, TRUP (Trupanion Inc.) holds a C grade (64/100 RQD, P/E 68.2x, ROIC 3.1%, cap $1.32B) and CSTL (Castle Biosciences Inc.) posts a C- grade (60/100 RQD, P/E N/A, ROIC -9.3%, cap $1.18B). Among the 5-stock peer group, TRUP leads on earnings multiple (68.2x) while ALHC leads on capital efficiency (13.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for FRNM?

Per FRNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002017526), Freenome Inc. generated $0 in revenue, $837.5K in net income, and -$864.7K in free cash flow against $92.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is FRNM trading relative to its 50-day, 200-day, and 52-week technical levels?

FRNM last traded at $12.86 (-4.32% on volume of 360,311 shares), positioning the stock -12.70% below its 50-day simple moving average ($14.73) and +2.80% above its 200-day simple moving average ($12.51). Across its 52-week range of $9.95 to $17.50, FRNM sits at the 38.5% percentile with a 14-day RSI of 39.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($11.25 to $14.47).

FRNM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Freenome Inc. (FRNM)?

In FY 2025 (10-K), FRNM converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: FRNM RQD Cockpit FRNM 12M Forecast FRNM Earnings & Move FRNM Dividends & DRIP FRNM Insiders & 13F FRNM Whale Options FRNM Profit Sankey FRNM News & Why